WO2010013969A3 - A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt - Google Patents

A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt Download PDF

Info

Publication number
WO2010013969A3
WO2010013969A3 PCT/KR2009/004277 KR2009004277W WO2010013969A3 WO 2010013969 A3 WO2010013969 A3 WO 2010013969A3 KR 2009004277 W KR2009004277 W KR 2009004277W WO 2010013969 A3 WO2010013969 A3 WO 2010013969A3
Authority
WO
WIPO (PCT)
Prior art keywords
salts
salt
benzamidine
alendronic acid
preventing
Prior art date
Application number
PCT/KR2009/004277
Other languages
French (fr)
Other versions
WO2010013969A2 (en
Inventor
Jin Soo Lee
Yun Ha Hwang
Jei Man Ryu
Jae Hoon Park
Duk Kyun Chung
Original Assignee
Dong Wha Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Wha Pharmaceutical Co., Ltd. filed Critical Dong Wha Pharmaceutical Co., Ltd.
Priority to JP2011521043A priority Critical patent/JP2011529875A/en
Priority to EP09803174A priority patent/EP2307015A4/en
Priority to CA2732863A priority patent/CA2732863A1/en
Priority to CN2009801335635A priority patent/CN102149380B/en
Publication of WO2010013969A2 publication Critical patent/WO2010013969A2/en
Publication of WO2010013969A3 publication Critical patent/WO2010013969A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition for preventing and treating osteoporosis, comprising N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, or salts thereof, and alendronic acid or a salt thereof. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or salts thereof and alendronic acid or a salt thereof exhibits excellent inhibitory effect on osteoclast differentiation, as compared to each individual treatment, thereby being useful for the prevention or treatment of osteoporosis.
PCT/KR2009/004277 2008-08-01 2009-07-31 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt WO2010013969A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2011521043A JP2011529875A (en) 2008-08-01 2009-07-31 Pharmaceutical composition for preventing or treating osteoporosis comprising a benzamidine derivative or a salt thereof and alendronic acid or a salt thereof
EP09803174A EP2307015A4 (en) 2008-08-01 2009-07-31 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt
CA2732863A CA2732863A1 (en) 2008-08-01 2009-07-31 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt
CN2009801335635A CN102149380B (en) 2008-08-01 2009-07-31 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080075792 2008-08-01
KR10-2008-0075792 2008-08-01

Publications (2)

Publication Number Publication Date
WO2010013969A2 WO2010013969A2 (en) 2010-02-04
WO2010013969A3 true WO2010013969A3 (en) 2010-05-27

Family

ID=41610865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/004277 WO2010013969A2 (en) 2008-08-01 2009-07-31 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt

Country Status (6)

Country Link
EP (1) EP2307015A4 (en)
JP (1) JP2011529875A (en)
KR (1) KR20100014173A (en)
CN (1) CN102149380B (en)
CA (1) CA2732863A1 (en)
WO (1) WO2010013969A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100014090A (en) * 2008-08-01 2010-02-10 동화약품주식회사 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
KR19980071076A (en) * 1997-02-04 1998-10-26 서홍석 3-amino-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
WO2003007947A1 (en) * 2001-07-19 2003-01-30 Dong Wha Pharm. Ind. Co., Ltd. Use of 4-[(4-thiazolyl)phenoxl] alkoxy-benzamidine derivatives for treatment of osteoporosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1144806A (en) * 1996-07-25 1997-03-12 南京药物研究所 Amino-diphosphinic acids bone absorption inhibitor and preparation method of its sodium salt
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
KR100317935B1 (en) * 1999-10-20 2001-12-22 유승필 Pharmaceutical compositions and preparations for treatment of metabolic bone disease
JP2003292453A (en) * 2002-04-02 2003-10-15 Asahi Kasei Corp Medicinal agent composition for treating bone disease
JPWO2005002590A1 (en) * 2003-07-01 2006-08-10 アステラス製薬株式会社 Bone mass increase inducer
WO2005039485A2 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
WO2005105091A1 (en) * 2004-04-28 2005-11-10 Merck & Co., Inc. Fluorinated 4-azasteroids as androgen receptor modulators
DE602005026667D1 (en) * 2004-07-05 2011-04-14 Dong Wha Pharm Ind Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BONE FRACTURES
JP2009017222A (en) * 2007-07-04 2009-01-22 Panasonic Corp Color adjustment apparatus, color adjustment method, and integrated circuit of color adjustment apparatus
KR20100014090A (en) * 2008-08-01 2010-02-10 동화약품주식회사 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
KR19980071076A (en) * 1997-02-04 1998-10-26 서홍석 3-amino-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
WO2003007947A1 (en) * 2001-07-19 2003-01-30 Dong Wha Pharm. Ind. Co., Ltd. Use of 4-[(4-thiazolyl)phenoxl] alkoxy-benzamidine derivatives for treatment of osteoporosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENNIS M. BLACK ET AL.: "The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 349, no. 13, 25 September 2003 (2003-09-25), pages 1207 - 1215, XP009045315 *
See also references of EP2307015A4 *

Also Published As

Publication number Publication date
CA2732863A1 (en) 2010-02-04
EP2307015A4 (en) 2012-05-16
CN102149380A (en) 2011-08-10
WO2010013969A2 (en) 2010-02-04
JP2011529875A (en) 2011-12-15
KR20100014173A (en) 2010-02-10
CN102149380B (en) 2012-12-05
EP2307015A2 (en) 2011-04-13

Similar Documents

Publication Publication Date Title
WO2010032875A3 (en) Heterocyclic carboxamide compounds
WO2011159067A3 (en) Thiazole derivatives as sglt2 inhibitors and pharmaceutical composition comprising same
WO2008136428A1 (en) Nitrogen-containing five-membered heterocyclic compound
WO2010057101A3 (en) Compounds useful as hiv blockers
WO2010021680A3 (en) Inhibitors of beta-secretase
WO2009080705A3 (en) Bis-thiazole derivatives, process for their preparation and their use as medicaments
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2011126903A3 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
GEP20125650B (en) Thiophene or thiazole derivatives and use thereof as pi3k inhibitors
WO2012009715A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
NZ595674A (en) Imidazo[2,1-b][1,3,4]thiadiazole derivatives
WO2011159129A3 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
NZ741318A (en) Compound for treating or preventing hyperuricemia or gout
WO2009019303A3 (en) A process for the preparation or purification of olmesartan medoxomil
NZ602125A (en) Uses of dgat1 inhibitors
NZ598750A (en) Therapeutic agent for mood disorders
NZ749427A (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same
MY187899A (en) (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
WO2009051223A1 (en) Pharmaceutical composition for treatment of cataract
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
MX351555B (en) Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1- methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimi dazol-2-yl]urea.
WO2010013969A3 (en) A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt
WO2012096934A3 (en) Inhibitors of retroviral replication
MX2019014078A (en) Urat1 inhibitor for promoting uric acid excretion.
WO2010013975A3 (en) A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980133563.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09803174

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2732863

Country of ref document: CA

Ref document number: 2011521043

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009803174

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE